Trials / Completed
CompletedNCT02163720
Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
Non Interventional Study Dealing With the Use of Trabectedin (Yondelis®)-Pegylated Liposomal Doxorubicin (Caelyx®) in Patient With Platinum-sensitive Relapse
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 101 (actual)
- Sponsor
- ARCAGY/ GINECO GROUP · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®, in ovarian platinum sensitive cancer relapse.
Detailed description
Population : Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal with platinum-sensitive recurrent witch it was decided to initiate a treatment with trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Yondelis®-Caelyx® | Observation of Yondelis®-Caelyx® administration |
Timeline
- Start date
- 2014-07-10
- Primary completion
- 2017-03-01
- Completion
- 2018-09-18
- First posted
- 2014-06-16
- Last updated
- 2020-09-30
Locations
33 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02163720. Inclusion in this directory is not an endorsement.